News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
701,760 Results
Type
Article (43045)
Company Profile (278)
Press Release (658437)
Section
Business (205395)
Career Advice (2020)
Deals (35548)
Drug Delivery (95)
Drug Development (81574)
Employer Resources (170)
FDA (16239)
Job Trends (14929)
News (347134)
Policy (32732)
Tag
2024 BioCapital Digital (6)
2024 BioForest Digital (1)
2024 BioForest Standard (1)
2024 BioMidwest Digital (7)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (5)
2024 Bio NC Standard (2)
2024 Biotech Bay Standard (18)
2024 Biotech Beach Digital (9)
2024 Biotech Beach Standard (4)
2024 Genetown Digital (5)
2024 Genetown Standard (9)
2024 Lone Star Bio Digital (5)
2024 Pharm Country Digital (6)
2024 Pharm Country Standard (5)
2025 BioForest Digital (1)
2025 Lone Star Bio Digital (5)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (1)
2026 Biotech Bay Standard (1)
2026 Biotech Beach Elite (1)
2026 Genetown Elite (2)
2026 Pharm Country Standard (1)
Academia (2622)
Accelerated approval (3)
Adcomms (23)
Allergies (78)
Alliances (49817)
ALS (77)
Alzheimer's disease (1331)
Antibody-drug conjugate (ADC) (100)
Approvals (16216)
Artificial intelligence (214)
Autoimmune disease (10)
Automation (14)
Bankruptcy (360)
Best Places to Work (11724)
BIOSECURE Act (19)
Biosimilars (92)
Biotechnology (203)
Bladder cancer (51)
Brain cancer (25)
Breast cancer (233)
Cancer (1817)
Cardiovascular disease (134)
Career advice (1681)
Career pathing (28)
CAR-T (133)
Cell therapy (382)
Cervical cancer (13)
Clinical research (65785)
Collaboration (712)
Compensation (403)
Complete response letters (20)
COVID-19 (2607)
CRISPR (33)
C-suite (185)
Cystic fibrosis (98)
Data (1737)
Decentralized trials (2)
Denatured (14)
Depression (36)
Diabetes (225)
Diagnostics (6375)
Digital health (17)
Diversity (8)
Diversity, equity & inclusion (45)
Drug discovery (109)
Drug pricing (96)
Drug shortages (25)
Duchenne muscular dystrophy (67)
Earnings (86056)
Editorial (28)
Employer branding (21)
Employer resources (146)
Events (112151)
Executive appointments (596)
FDA (17226)
Featured Employer (54)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (7)
Funding (636)
Gene editing (91)
Generative AI (19)
Gene therapy (270)
GLP-1 (668)
Government (4400)
Grass and pollen (4)
Guidances (46)
Healthcare (18912)
Huntington's disease (22)
IgA nephropathy (19)
Immunology and inflammation (92)
Indications (23)
Infectious disease (2726)
Inflammatory bowel disease (129)
Inflation Reduction Act (8)
Influenza (43)
Intellectual property (71)
Interviews (315)
IPO (16536)
IRA (40)
Job creations (3652)
Job search strategy (1432)
Kidney cancer (9)
Labor market (27)
Layoffs (450)
Leadership (14)
Legal (7946)
Liver cancer (71)
Lung cancer (268)
Lymphoma (123)
Machine learning (2)
Management (57)
Manufacturing (248)
MASH (58)
Medical device (13300)
Medtech (13305)
Mergers & acquisitions (19418)
Metabolic disorders (588)
Multiple sclerosis (59)
NASH (16)
Neurodegenerative disease (71)
Neuropsychiatric disorders (24)
Neuroscience (1768)
NextGen: Class of 2025 (6580)
Non-profit (4544)
Northern California (2233)
Now hiring (36)
Obesity (323)
Opinion (201)
Ovarian cancer (61)
Pain (72)
Pancreatic cancer (70)
Parkinson's disease (119)
Partnered (17)
Patents (183)
Patient recruitment (82)
Peanut (45)
People (57343)
Pharmaceutical (63)
Pharmacy benefit managers (18)
Phase I (20544)
Phase II (28961)
Phase III (21558)
Pipeline (816)
Podcasts (42)
Policy (103)
Postmarket research (2584)
Preclinical (8716)
Press Release (67)
Prostate cancer (84)
Psychedelics (31)
Radiopharmaceuticals (243)
Rare diseases (353)
Real estate (5938)
Recruiting (64)
Regulatory (22190)
Reports (43)
Research institute (2415)
Resumes & cover letters (352)
Rett syndrome (3)
RNA editing (1)
RSV (36)
Schizophrenia (60)
Series A (116)
Series B (69)
Service/supplier (12)
Sickle cell disease (52)
Southern California (1915)
Special edition (14)
Sponsored (28)
Startups (3623)
State (2)
Stomach cancer (12)
Supply chain (56)
The Weekly (27)
United States (19699)
Vaccines (638)
Venture capitalists (35)
Webinars (12)
Weight loss (218)
Women's health (30)
Worklife (13)
Date
Last 7 days (674)
Last 30 days (2734)
Last 365 days (34230)
2025 (5930)
2024 (35482)
2023 (40319)
2022 (51526)
2021 (56037)
2020 (54397)
2019 (46868)
2018 (35298)
2017 (32458)
2016 (31917)
2015 (37926)
2014 (31652)
2013 (26838)
2012 (29017)
2011 (29667)
2010 (27744)
Location
Africa (742)
Alabama (48)
Alaska (7)
Arizona (214)
Arkansas (12)
Asia (38072)
Australia (6269)
California (5104)
Canada (1774)
China (420)
Colorado (232)
Connecticut (246)
Delaware (111)
Europe (82178)
Florida (750)
Georgia (174)
Idaho (57)
Illinois (468)
India (21)
Indiana (276)
Iowa (7)
Japan (128)
Kansas (99)
Kentucky (24)
Louisiana (7)
Maine (60)
Maryland (784)
Massachusetts (3892)
Michigan (203)
Minnesota (348)
Mississippi (2)
Missouri (72)
Montana (27)
Nebraska (25)
Nevada (54)
New Hampshire (61)
New Jersey (1447)
New Mexico (27)
New York (1460)
North Carolina (885)
North Dakota (7)
Northern California (2233)
Ohio (179)
Oklahoma (13)
Oregon (32)
Pennsylvania (1164)
Puerto Rico (6)
Rhode Island (24)
South America (1115)
South Carolina (15)
South Dakota (1)
Southern California (1915)
Tennessee (84)
Texas (755)
Utah (155)
Virginia (118)
Washington D.C. (55)
Washington State (497)
West Virginia (3)
Wisconsin (44)
701,760 Results for "fulgent genetics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
February 28, 2025
·
14 min read
Business
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it will release its first quarter 2024 financial results before the market opens on Friday, May 3, 2024.
April 11, 2024
·
1 min read
Business
Fulgent Reports First Quarter 2024 Financial Results
Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced financial results for its first quarter ended March 31, 2024.
May 3, 2024
·
13 min read
BioMidwest
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
Moffitt Cancer Center, a world-renowned cancer treatment and research center, and Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced a strategic partnership aimed at advancing cancer treatment through clinical development and pre-clinical co-development initiatives.
May 14, 2024
·
6 min read
Press Releases
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
February 6, 2025
·
1 min read
Press Releases
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans1
October 31, 2024
·
6 min read
Biotech Beach
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
Fulgent Pharma, a subsidiary of Fulgent Genetics, Inc. and a leading nanobiotechnology company specializing in innovative cancer therapeutics, announced that Phase 1 clinical data on its lead therapeutic development candidate, FID-007, to treat Head and Neck cancer, will be presented at the American Society for Clinical Oncology Annual Meeting on June 2, 2024 in Chicago, Illinois.
May 24, 2024
·
5 min read
Business
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
Fulgent Genetics, Inc. today announced that it will release its fourth quarter and full year 2023 financial results before the market opens on Wednesday, February 28, 2024.
February 13, 2024
·
1 min read
Business
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
Fulgent Genetics, Inc. today announced financial results for its fourth quarter and full year ended December 31, 2023.
February 28, 2024
·
16 min read
Press Releases
Fulgent Reports Third Quarter 2024 Financial Results
November 8, 2024
·
14 min read
1 of 70,176
Next
